367 Pharmacokinetic and immunologic data from a phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform

• Vivek Subbiah,
• Alexander Guminski,
• James Strauss,
• Vivek Bhadri,
• Nam Bui,
• Jose Mejia Oneto,
• M Wayne Saville,
• Sangeetha Srinivasan,
• Nathan Yee,
• Michael Zakharian,
• Sant Chawla,
• Vineet Kwatra,
• Mia Weiss,
• Rosalind Wilson

Affiliations

Vivek Subbiah

Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Alexander Guminski

3Royal North Shore Hospital, St Leonards, Australia

James Strauss

2Mary Crowley Cancer Research Center, Dallas, TX, USA

Vivek Bhadri

1Chris O’Brien Lifehouse, Camperdown, Australia

Nam Bui

2Stanford Cancer Institute, Palo Alto, CA, USA

Jose Mejia Oneto

4Shasqi, Inc., San Francisco, CA, USA

M Wayne Saville

4Shasqi, Inc., San Francisco, CA, USA

Sangeetha Srinivasan

4Shasqi, Inc., San Francisco, CA, USA

Nathan Yee

4Shasqi, Inc., San Francisco, CA, USA

Michael Zakharian

1Shasqi, Inc., San Francisco, CA, USA

Sant Chawla

4Sarcoma Oncology Santa Monica, Santa Monica, CA, USA

Vineet Kwatra

6Cancer Research South Australia, Adelaide, Australia

Mia Weiss

7Washington University, St. Louis, St. Louis, MO, USA

Rosalind Wilson

9Shasqi, Inc., San Francisco, CA, USA